2012
Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT).
Winer E, Tolaney S, Nechushtan H, Berger R, Kurzrock R, Ron I, Schoffski P, Awada A, Yasenchak C, Burris H, Ramies D, Rafferty T, Shen X. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical Oncology 2012, 30: 535-535. DOI: 10.1200/jco.2012.30.15_suppl.535.Peer-Reviewed Original ResearchProgression-free survivalMetastatic breast cancerBone scanTumor regressionWk 12Common grade 3/4 AEsMedian progression-free survivalPost-baseline tumour assessmentActivity of cabozantinibGrade 5 AEsMedian age 56Median prior linesObjective response rateObjective tumor regressionStudy days 1Breast cancer developmentDysregulation of METBone painEligible patientsEvaluable ptsMeasurable diseasePrior anthracyclineSerum NTxImproved painPrimary endpoint
2011
P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial.
Tolaney S, Nechushtan H, Berger R, Kurzrock R, Ron I, Schöffski P, Awada A, Yasenchak C, Burris H, Ramies D, Shen X, Winer E. P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial. Cancer Research 2011, 71: p1-17-10-p1-17-10. DOI: 10.1158/0008-5472.sabcs11-p1-17-10.Peer-Reviewed Original ResearchMetastatic breast cancerObjective response rateStable diseasePartial responseBone scanBreast cancerBone metastasesNarcotic useDiscontinuation trialClinical activityWk 12Common related adverse eventsOverall disease control ratePost-baseline tumour assessmentPrior anti-VEGF therapyBone marker analysesFatigue/astheniaPrior treatment regimensPrior treatment statusDisease control rateHand-foot syndromeProgression-free survivalRelated adverse eventsAnti-VEGF therapyInvasive ductal carcinoma
2007
Surveillance Testing Among Survivors of Early-Stage Breast Cancer
Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance Testing Among Survivors of Early-Stage Breast Cancer. Journal Of Clinical Oncology 2007, 25: 1074-1081. PMID: 17369571, DOI: 10.1200/jco.2006.08.6876.Peer-Reviewed Original ResearchMeSH KeywordsAgedBreast NeoplasmsCohort StudiesDiagnostic Tests, RoutineFemaleFollow-Up StudiesGuideline AdherenceHumansLogistic ModelsLong-Term CareMedical OncologyNeoplasm StagingOdds RatioOffice VisitsPopulation SurveillancePractice Guidelines as TopicPractice Patterns, Physicians'Primary Health CareSEER ProgramSurvivorsTime FactorsUnited StatesUnnecessary ProceduresConceptsBreast cancer survivorsChest X-rayMedical oncologistsCancer survivorsBreast cancerAbdominal imagingAntigen testingBone scanStage I/II breast cancerEarly-stage breast cancer patientsMost breast cancer survivorsEnd Results-Medicare dataSurveillance testingEarly-stage breast cancerRepeated-measures logistic regressionBreast cancer patientsLow-risk populationPopulation-based cohortTypes of physiciansRoutine surveillance testingRate of testingAntigen testCancer patientsWomen's ageSurveillance years